Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
Biochem Biophys Res Commun ; 458(3): 596-600, 2015 Mar 13.
Artigo em Inglês | MEDLINE | ID: mdl-25680470

RESUMO

To explore the association of the phenotype of ATP-activated current with the genotype of P2X1-6 subunits in nociceptors, we developed a method that allows us to label nociceptive neurons innervating tooth-pulp in rat trigeminal ganglion (TG) neurons using a retrograde fluorescence-tracing method, to record ATP-activated current in freshly isolated fluorescence-labeled neurons, and then to conduct single cell immunohistochemical staining for P2X1-6 subunits in the same neuron. We found that fast application of 100 µM ATP to fluorescence-traced TG neurons produced robust inward current in 87% (96/110) of cells tested. The diameter of cells varied from 16 to 56 µm. Three types of ATP-activated current (F, I and S) were recorded with distinct rise times of the current (R10-90, P < 0.05). There was a positive correlation between the cell diameter and the value of R10-90 (P < 0.05): the value of R10-90 increased with increases in the cell diameter. Cells responsive to ATP with the type F current mainly showed positive staining for P2X3 and P2X5, but negative staining for P2X2; cells responsive to ATP with the type I current showed positive staining for P2X1-3 and P2X5, but negative staining for P2X4; and cells responsive to ATP with the type S current showed positive staining for P2X1-5, but negative staining for P2X6. The present findings suggest that in addition to P2X3 subunits, P2X5 subunits are also involved in the generation of the F type of ATP-activated current in small-sized nociceptive neurons. In addition to the P2X2/3 subunit-containing channels, more complex uncharacterized combinations of P2X1-5 subunits exist in native medium-sized nociceptive neurons exhibiting the I and S types of ATP-activated current. In addition, the P2X6 subunit is not a main subunit involved in the nociceptive signal in rat TG neurons innervating tooth-pulp.


Assuntos
Trifosfato de Adenosina/metabolismo , Polpa Dentária/inervação , Neurônios/citologia , Receptores Purinérgicos P2X/metabolismo , Receptores Purinérgicos P2/metabolismo , Animais , Células Cultivadas , Genótipo , Imuno-Histoquímica , Neurônios/metabolismo , Técnicas de Patch-Clamp , Subunidades Proteicas/genética , Subunidades Proteicas/metabolismo , Ratos , Ratos Sprague-Dawley , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2X/genética , Gânglio Trigeminal/citologia
2.
Gut ; 63(11): 1728-36, 2014 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-24515806

RESUMO

OBJECTIVE: Previous studies have shown that ulcerative colitis (UC) is associated with the presence of lamina propria non-invariant (Type II) NKT cells producing IL-13 and mediating epithelial cell cytotoxicity. Here we sought to define the antigen(s) stimulating the NKT cells and to quantitate these cells in the UC lamina propria. DESIGN: Detection of Type II NKT cells in UC lamina propria mononuclear cells (LPMC) with lyso-sulfatide loaded tetramer and quantum dot-based flow cytometry and staining. Culture of UC LPMCs with lyso-sulfatide glycolipid to determine sulfatide induction of epithelial cell cytotoxicity, IL-13 production and IL-13Rα2 expression. Blinded quantum dot-based phenotypic analysis to assess UC LPMC expression of IL-13Rα2, CD161 and IL-13. RESULTS: Approximately 36% of UC LPMC were lyso-sulfatide tetramer positive, whereas few, if any, control LPMCs were positive. When tested, the positive cells were also CD3 and IL-13Rα2 positive. Culture of UC LPMC with lyso-sulfatide glycolipid showed that sulfatide stimulates UC LPMC production of IL-13 and induces UC CD161 LPMC-mediated cytotoxicity of activated epithelial cells; additionally, lyso-sulfatide induces enhanced expression of IL-13Rα2. Finally, blinded phenotypic analysis of UC LP MC using multicolour quantum dot-staining technology showed that approximately 60% of the LPMC bear both IL-13Rα2 and CD161 and most of these cells also produce IL-13. CONCLUSIONS: These studies show that UC lamina propria is replete with Type II NKT cells responsive to lyso-sulfatide glycolipid and bearing IL-13Rα2. Since lyso-sulfatide is a self-antigen, these data suggest that an autoimmune response is involved in UC pathogenesis.


Assuntos
Autoantígenos/imunologia , Colite Ulcerativa/imunologia , Subunidade alfa2 de Receptor de Interleucina-13/imunologia , Mucosa Intestinal/imunologia , Subpopulações de Linfócitos/imunologia , Células T Matadoras Naturais/imunologia , Glicolipídeos , Humanos , Técnicas In Vitro , Psicosina/análogos & derivados , Psicosina/imunologia , Regulação para Cima/imunologia
3.
J Huazhong Univ Sci Technolog Med Sci ; 33(3): 423-426, 2013 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-23771671

RESUMO

We developed a method that allows us to label nociceptive neurons innervating tooth-pulp in rat trigeminal ganglion neurons using a retrograde fluorescence-tracing method, to record ATP-activated current in freshly isolated fluorescence-labeled neurons and to conduct single cell immunohistochemical staining for P2X1 and P2X3 subunits in the same neuron. Three types of ATP-activated current in these neurons (F, I and S) were recorded. The cells exhibiting the type F current mainly showed positive staining for P2X3, but negative staining for P2X1. The results provide direct and convincing evidence at the level of single native nociceptive neurons for correlation of the characteristics of ATP-activated currents with their composition of P2X1 and P2X3 subunits and cell size. The results also suggest that the P2X3, but not P2X1, is the main subunit that mediates the fast ATP-activated current in nociceptive neurons.


Assuntos
Trifosfato de Adenosina/metabolismo , Polpa Dentária/inervação , Polpa Dentária/fisiologia , Nociceptores/fisiologia , Receptores Purinérgicos P2X3/metabolismo , Nervo Trigêmeo/metabolismo , Potenciais de Ação/fisiologia , Animais , Nociceptores/citologia , Ratos , Ratos Sprague-Dawley , Receptores Purinérgicos P2X1/metabolismo , Distribuição Tecidual , Nervo Trigêmeo/citologia
4.
Gut ; 60(4): 449-55, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-20971977

RESUMO

OBJECTIVE: Ulcerative colitis is associated with increased interleukin 13 (IL-13) production by natural killer T cells. Taking advantage of the inhibitory actions of interferon ß on IL-13 expression, this proof-of-concept study aimed to show that decreasing IL-13 production is associated with clinical improvement of ulcerative colitis symptoms. DESIGN: Open-label interventional drug trial. SETTING: Outpatient clinical research hospital. Patients Adult patients with active ulcerative colitis (Short Clinical Colitis Activity Index (SCCAI)≥ 5). Interventions Treatment with 30 µg IM interferon-ß-1a (Avonex) weekly for 12 weeks with 6 month follow-up. MAIN OUTCOME MEASURES: Clinical response was defined as ≥ 3 point drop in the SCCAI for at least two consecutive monitoring visits, and cytokine production was measured in cultured peripheral blood and lamina propria mononuclear cells (LPMC) before and after treatment. RESULTS: 11 of 16 patients were clinical responders, and 4 were in remission (SCCAI ≤ 2) at the end of treatment. Rectal bleeding subscores improved dramatically by week 4 (38% with frank bleeding vs 87% pretreatment). Increased IL-13 production by LPMC T cells fell significantly in clinical responders (690 ± 99 vs 297 ± 58 pg/ml p = 0.015) but was unchanged in non-responders (542 ± 83 vs 510 ± 39 pg/ml). In addition, non-responders had significantly higher production of IL-17 and IL-6 pre-treatment compared to responders. CONCLUSIONS: Interferon-ß-1a induces clinical response and remission in a large subset of patients with ulcerative colitis that is associated with significant inhibition of IL-13 production. In addition, increased IL-17 and IL-6 production is associated with no response to interferon-ß. These data provide a proof-of-concept that IL-13 is an effector cytokine in ulcerative colitis and should be a target for novel therapies.


Assuntos
Colite Ulcerativa/tratamento farmacológico , Fármacos Gastrointestinais/uso terapêutico , Interferon beta/uso terapêutico , Interleucina-13/biossíntese , Adolescente , Adulto , Idoso , Linfócitos T CD4-Positivos/imunologia , Células Cultivadas , Colite Ulcerativa/imunologia , Citocinas/biossíntese , Feminino , Seguimentos , Fármacos Gastrointestinais/efeitos adversos , Humanos , Interferon beta-1a , Interferon beta/efeitos adversos , Masculino , Pessoa de Meia-Idade , Resultado do Tratamento , Adulto Jovem
5.
Biochem Biophys Res Commun ; 381(1): 102-6, 2009 Mar 27.
Artigo em Inglês | MEDLINE | ID: mdl-19351603

RESUMO

Relatively little information is available about the molecular mechanism of ethanol inhibition of P2X receptors. Here, we investigated the possibility that 10 conserved cysteine residues in the extracellular loop of the rat P2X4 receptor may regulate ethanol inhibition of the receptor using a series of individual cysteine to alanine point mutations. Each of the mutated receptors generated robust inward current in response to ATP and the mutations produced less than a sixfold change in the ATP EC50 value. For the C116A, C126A, C149A, and C165A mutants, 100 mM ethanol did not significantly affect the current activated by an EC40 concentration of ATP. By contrast, for the C261A and C270A mutants, ethanol inhibited ATP-activated current in a competitive manner similar to that for the wild-type receptor. Interestingly, for the C132A, C159A, C217A, and C227A mutants, ethanol inhibited ATP-activated current, but decreased the maximal response to ATP by 70-75% without significantly changing the EC50 value of ATP, thus exhibiting a noncompetitive-type inhibition. The results suggest that cysteines and disulfide bonds between cysteines are differentially involved in the inhibition of the rat P2X4 receptor by ethanol.


Assuntos
Cisteína/metabolismo , Etanol/toxicidade , Antagonistas do Receptor Purinérgico P2 , Receptores Purinérgicos P2/metabolismo , Sequência de Aminoácidos , Animais , Sequência Conservada , Cisteína/genética , Mutação , Ratos , Receptores Purinérgicos P2/genética , Receptores Purinérgicos P2X4 , Xenopus
6.
Biotechniques ; 39(5): 741-51, 2005 Nov.
Artigo em Inglês | MEDLINE | ID: mdl-16312221

RESUMO

A unique array-based pathogen chip has been developed for the detection of viral RNA or DNA relevant to pathologies of the central nervous system. A total of 715 unique oligonucleotides (60-mer) representing approximately 100 pathogens were designed based on open reading frames (ORFs) from highly conserved and heterogenic regions within viral families. In addition, viral genes reflecting different stages of pathogen infection were also included to potentially define the stage of the viral infection. Viruses (double-stranded DNA, double- or single-stranded RNA, delta, retroid), parasites, and bacteria were included. Test samples labeled with Cy5 were examined by cohybridization with a reference RNA, labeled with Cy3, to the pathogen microarray chip. Good reproducibility of experiments was observed, based on data generated from duplicate hybridizations and duplicate spots on the microarray platform. A viral transcript detection sensitivity of 1 x 10(3) plaque-forming units (pfus) was achieved using selected cell lines and viruses. These findings suggest that the array-based platform described here is capable of detecting a broad spectrum of viruses in a single assay with relatively high sensitivity, specificity, and reproducibility. This method may be used to provide evidence of viral infection in postmortem tissue from psychiatric patients as well as a wide range of other diagnostic categories.


Assuntos
Encéfalo/virologia , Autopsia , Carbocianinas/farmacologia , Linhagem Celular , Linhagem Celular Tumoral , Análise por Conglomerados , DNA Viral/metabolismo , Bases de Dados Genéticas , Genoma , Herpesvirus Humano 1/metabolismo , Humanos , Hibridização de Ácido Nucleico , Análise de Sequência com Séries de Oligonucleotídeos , Oligonucleotídeos/análise , Oligonucleotídeos/química , Fases de Leitura Aberta , RNA Antissenso/análise , RNA Mensageiro/metabolismo , RNA Viral/análise , RNA Viral/metabolismo , Sensibilidade e Especificidade
7.
Eur J Pharmacol ; 707(1-3): 11-6, 2013 May 05.
Artigo em Inglês | MEDLINE | ID: mdl-23524095

RESUMO

One feature of the amino acid sequence of P2X receptors identified from mammalian species, Xenopus laevis and zebrafish is the conservation of ten cysteines in the extracellular loop. Little information is available about the role of these conserved ectodomain cysteines in the function of P2X receptors. Here, we investigated the possibility that ten conserved cysteine residues in the extracellular loop of the rat P2X4 receptor may regulate zinc potentiation of the receptor using a series of individual cysteine to alanine point mutations and functional characterization of recombinant receptors expressed in Xenopus oocytes. For the C116A, C132A, C159A, C165A, C217A and C227A mutants, 10 µM zinc did not significantly affect the current activated by an EC40 concentration of ATP. By contrast, 5 µM zinc shifted the ATP concentration-response curve to the right in a parallel manner for both the C261A and C270A mutants and the magnitudes of those shifts were similar to that of the wildtype receptor. Interestingly, for the C126A and C149A mutants, 5µM zinc potentiated ATP-activated current, but increased the maximal response to ATP by 90% and 81% respectively, without significantly changing the EC50 value of ATP. Thus, these results suggest that cysteines and disulfide bonds between cysteines are differentially involved in the potentiation of the rat P2X4 receptor by zinc.


Assuntos
Trifosfato de Adenosina/administração & dosagem , Cisteína/metabolismo , Receptores Purinérgicos P2X4/metabolismo , Zinco/farmacologia , Sequência de Aminoácidos , Animais , Sequência Conservada , Cisteína/química , Dissulfetos/química , Relação Dose-Resposta a Droga , Feminino , Oócitos , Mutação Puntual , Ratos , Receptores Purinérgicos P2X4/química , Receptores Purinérgicos P2X4/genética , Especificidade da Espécie , Xenopus laevis
8.
Gastroenterology ; 131(3): 748-56, 2006 Sep.
Artigo em Inglês | MEDLINE | ID: mdl-16952544

RESUMO

BACKGROUND & AIMS: Common variable immunodeficiency (CVID) patients can develop an idiopathic inflammatory bowel disease resulting in chronic diarrhea and life-threatening malabsorption. This study was designed to assess the status of the gastrointestinal tract and to define the mucosal immune abnormalities in patients with and without symptomatic gut inflammatory disease. METHODS: CVID patients underwent tests of gut absorption, peripheral blood mononuclear cell phenotyping, and upper and lower endoscopy for histology and lamina propria mononuclear cell (LPMC) cytokine production. RESULTS: CVID patients with gastrointestinal symptoms differed from asymptomatic CVID patients by having significantly longer duration of disease and lower body mass index, D-xylose absorption, serum albumin, CD4/CD45RA cells, CD3/CD25 cells, and natural killer cells. Symptomatic CVID patients showed diffuse histologic inflammatory changes in the duodenal and colonic mucosa including villus blunting, increased lamina propria and intraepithelial lymphocytes, and epithelial apoptosis, less frequently seen in asymptomatic patients. LPMCs from symptomatic CVID patients produced significantly higher T-helper (Th) 1 cytokines, interleukin-12, and interferon-gamma. Compared with the Th1 cytokines produced by LPMCs from Crohn's disease, CVID patients did not produce excess amounts of interleukin-23, interleukin-17, or tumor necrosis factor-alpha. CONCLUSIONS: The idiopathic inflammatory bowel disease associated with gastrointestinal symptoms in CVID is a unique combination of diverse histologic findings accompanied by excessive Th1 cytokine production, distinct from that in Crohn's disease. These data show that human gut mucosal inflammatory disease can occur with excess interleukin-12 and interferon-gamma production alone and provide a rationale for developing targeted therapies for this complication of CVID.


Assuntos
Imunodeficiência de Variável Comum/metabolismo , Doenças Inflamatórias Intestinais/metabolismo , Interleucina-12/metabolismo , Interleucinas/metabolismo , Adulto , Biomarcadores/metabolismo , Biópsia , Células Cultivadas , Imunodeficiência de Variável Comum/complicações , Imunodeficiência de Variável Comum/imunologia , Progressão da Doença , Endoscopia Gastrointestinal , Feminino , Seguimentos , Humanos , Doenças Inflamatórias Intestinais/complicações , Doenças Inflamatórias Intestinais/imunologia , Interleucina-23 , Subunidade p19 da Interleucina-23 , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patologia , Masculino , Pessoa de Meia-Idade , Prognóstico , Estudos Retrospectivos , Células Th1/imunologia , Células Th1/patologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA